Consulting and PK/PD Modelling Services for Preclinical and Clinical Biotherapeutics Development

 
Antibodies

Antibodies

Bi-specifics

Bi-specifics

Antibody-Drug Conjugates (ADCs)

Antibody-Drug Conjugates (ADCs)

Nanobodies

Nanobodies

Fab Fragments

Fab Fragments

Cell Based Therapies

Cell Based Therapies

siRNAs

siRNAs

 

Mission

We support the translation of innovation into pharmacological concepts and therapies. We believe that the most innovative therapeutic ideas deserve the best development tools. We use Systems Pharmacology as a key tool to maximize the success of your preclinical program, clinical study or registration.

Services

Our services includes consultancy and implementation of systems pharmacology and PK/PD modelling for target assessment, format selection, compound design, candidate selection, design and analysis of preclinical PK/PD and GLP toxicology studies, first in human dose selection, paediatric dose selection  and dose / regimen finding studies.

Why choose us

Our methods have been successfully applied in global pharmaceutical companies with tangible results including patents. We have the unique tested expertise developing bi-specifics, antibody-drug conjugates, scFv’s, nanobodies, cell based therapies to provide tailored support for your program.

Partners

label_web_iBxN_withBGLYO-X is member of the iBx Network. We provide integrated consulting in toxicology, pathology, preclinical and clinical pharmacology and regulatory strategies.

lixoft_labelLYO-X is partnering with Lixoft to provide you access to Monolix the scientifically and technologically most advanced software for preclinical and clinical data analysis.

 

LYO-X Kurzgesagt

Small Data Big Results

Learn more why Systems Pharmacology is a critical tool for the development of novel Biologics

  • Towards a novel acute treatment of stroke

    June 28, 2019

    Safety and Tolerability, Pharmacokinetics, and Pharmacodynamics of ACT017, an Antiplatelet GPVI (Glycoprotein VI) Fab Christine Voors-Pette, Kristell Lebozec, Peter Dogterom, Laurie Jullien, Philippe Billiald, Pauline Ferlan, Lionel Renaud, Olivier Favre-Bulle, Gilles Avenard, Matthias Machacek, Yannick Plétan, Martine Jandrot-Perrus. Arterioscler Thromb Vasc Biol. 2019;39:956-964.

  • ECCMID 2019 in Amsterdam

    April 4, 2019

    We will be at ECCMID 2019 with a poster contribution and as an exhibitor. The poster is on a novel cUTI mouse model and the application of PK/PD modelling to derive the required effect in the mouse model that translates to clinical response. We used historical Levofloxacin data to establish … Read More

  • EPFL Industry Day

    March 17, 2019

    LYO-X is excited to be invited to present at the EPFL Industry Day March 20th. We are rather proud to be among this illustrious line-up of companies: We hope to see you on the Industry Pitch March 20th or to welcome you at our booth the next day.

  • LYO-X joint BEAM to Fight Antimicrobial Resistance

    February 6, 2019

    LYO-X joint the BEAM (Biotech companies in Europe combating AntiMicrobial Resistance) alliance, a strong Network of ~ 50 European biopharmaceutical companies committed to developing innovative products to fend-off antibiotic-resistant pathogens. We have continuously expanded our support of biotech companies with PK/PD modelling and SystemsPharmacology to translate their antibiotics more effectively … Read More